• Skip to primary navigation
  • Skip to main content
  • Skip to footer

Target ALS

A New York based ALS research organization that's leading the fight for a cure.

  • DONATE
  • About Us
    • Our Mission
    • Our Impact
    • Our Team
    • Our Partners
  • For Scientists
    • Research Core Facilities
      • Longitudinal Biofluids Core
      • Human Postmortem Tissue Core
      • Genomic Datasets
      • Animal Models
      • In Vivo Target Validation Core
      • Stem Cell Core
      • Antibody Core
      • Viral Vector Core
    • Funding Opportunities
    • Funded Consortia
    • Annual Meeting
  • ALS Resources
    • The Science, Explained
    • Glossary
    • FAQ
    • Blog
    • Video Library
  • Take Action
    • Contact Us
    • Email Sign Up
    • Donate Now
    • Ways to Give
    • Donate Biofluid Samples
    • Corporate Council

Our Challenge

Barriers to Progress

Over the more than 150-year period since ALS was first described, little happened because of our lack of knowledge of the nervous system and of the disease itself. In the last two decades, a veritable explosion of promising basic science took place including the discovery of new ALS genes and new candidate therapeutic targets.

Despite advances in understanding ALS, critical tools and resources for scientists to test ideas had been missing.

Yet despite these discoveries, ALS remained an incurable disease.
Why? A series of mutually-reinforcing barriers were standing in the way, including:

Gaps in Funding: Few funding opportunities supported the translation of basic science ideas into validated drug targets and treatments.

Siloed Research: ALS researchers were operating in traditional silos, competing with each other rather than collaborating.

Lack of Scientific Resources : Researcher lacked access to the tools and resources necessary to advance promising ideas.

Limited Industry Investment: Given the limitations of translating ideas into the clinic, industry saw ALS as a high-risk area.

Bias in Funding Decisions: ALS research funding relied on a peer review process with inherent conflicts of interest.

Intellectual Property Restrictions: ALS scientists needed access to data and resources with no strings attached.

We developed an innovative model to empower researchers through collaboration, supported by funding and cutting edge tools, known as The Target ALS Innovation Ecosystem.

Unmatched in ALS research, our Innovation Ecosystem is a radically different approach to drug discovery breakthroughs, which we believe will lead to the first viable treatments for ALS.

Learn More

Footer

  • Challenge
  • Contact
  • Our Approach
  • Resources For Scientists
  • Donate
  • Call For Proposals
  • Funded Consortia
  • Annual Meeting
  • Privacy Policy
  • Credits

Follow Us

guidestar charity-navigator

The Target ALS (TALS) website is intended for informational purposes only. Opinions expressed may not be that of TALS or its employees. For more information about our digital policies, click here.

© 2022 Target ALS Foundation, Inc.
Target ALS Foundation
P.O. Box 1598
New York, NY 10101
(332) 333-4140
Steck Insights WordPress Consulting